Author: Charmaine Fraser

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company's annual general meeting, held earlier today at the Company’s offices in Oxford, were duly passed. Voting was conducted by a show of hands and inclusive of votes received by the...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that Dr Peter Sargent, Chief Executive Officer and Director of the Company, has acquired, via market purchases, 459,090 new ordinary shares of 0.4p in the Company (“Ordinary Shares”) at a price of 0.66p per Ordinary Share.   Click here to read in full...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the hiring this week of a new senior member of its team, Dr Mark Davies, as Head of Quantitative Pharmacology and Data Science.   Dr Mark Davies brings over 20 years’ experience in drug development, both from the perspective of...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a new contract by an existing client Cancer Research UK. The project involves the development of Pharmacokinetic Pharmacodynamic (PK/PD)* model to simulate the exposure-response relationship for a novel oncology therapy to guide starting...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to provide notice of the Company’s Annual General Meeting (“AGM”).   The AGM will be held at 10.30 a.m. on 19 November 2024 at the Company’s registered office, Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire, OX14 4SB.   Shareholders will shortly be sent either...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update in-line with its End of Year results via Investor Meet Company and has updated its website with the presentation.   The presentation and Q&A from the meeting are now available at the Company’s website: https://www.physiomics.co.uk/portfolio-item/investor-presentation-full-year-results-and-company-update/       Enquiries:   Physiomics plc Dr Jim Millen, Non-Executive...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the official launch of its Biostatistics offering and expansion of its Data Science and Bioinformatics services.   Leveraging its existing expertise and capabilities across the core Modelling and Simulation service line, the Company is moving forward to expand its offering into...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce its audited results for its financial year ended 30 June 2024.   Click here to read in full....

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it expects to release its audited results for the financial year ended 30 June 2024 during the last week of September 2024.   Dr Peter Sargent (CEO) and Dr Jim Millen (Non-Executive Chairman) will provide a live presentation relating to...